GLP-1 medications may carry serious risks, including thyroid C-cell tumor warnings, pancreatitis, gallbladder problems, kidney complications, gastrointestinal side effects, an increased risk of low blood sugar when used alongside certain diabetes medications, allergic reactions, pregnancy-related warnings, and other medication-specific risks
For instance, according to a research article published by the National Institutes of Health (NIH) in December 2020, titled Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus, it was found that oral nano drug delivery systems for phytocompounds aimed at treating T2DM not only retain the benefits of oral administration but also address the limitations of traditional oral drug delivery methods
These findings support the theory that the 2.5x greater concentration of semaglutide in Wegovy amplifies the frequency of gastroparesis-related symptoms
However, compounded versions are not identical to the original prescription drug, and their consistency can vary
Victoza, a GLP-1 drug released in 2010, had side effects discovered about it, eventually resulting in official warning from the FDA in 2013
